Phase I Study of ETEC Vaccine

NCT01147445 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

NIH

Sponsor class

Conditions

Gastroenteritis Escherichia Coli

Interventions

BIOLOGICAL: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)